7
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3258 |
Ponesimod
ACT-128800 |
S1P Receptor; LPL Receptor | GPCR/G Protein |
Ponesimod (ACT-128800) 是一种选择性 S1P1可口服激动剂,在放射性配体结合试验中的 IC50值为 6 nM。它可高效激活 S1P1介导的信号转导,EC50为5.7 nM。它可预防淋巴细胞介导的组织炎症,具有潜在的免疫调节活性。 | |||
T3626 |
Acalabrutinib
ACP-196,阿可替尼 |
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
Acalabrutinib (ACP-196) 是一种不可逆的、高效的、具有口服活性、选择性的第二代BTK 抑制剂。它与 BTK 的 ATP 结合口袋中的 Cys481 共价结合。它在慢性淋巴细胞性白血病 (CLL) 小鼠模型中显示出强大的靶向作用和功效。 | |||
T28708 |
Sch 24937
|
||
Sch 24937 is a potent immunosuppressant on B lymphocyte mediated immune responses. | |||
T37675 |
3-Deaza-2'-deoxyadenosine
|
||
3-Deaza-2'-deoxyadenosine strongly inhibits lymphocyte-mediated cytolysis with low cytotoxicity when applied at 100 μM. This nucleoside can also be used to evaluate the role of the adenine N3 nitrogen in DNA structure and function. | |||
T3977L |
Lifitegrast sodium
SAR-1118-023,SAR1118-023,SAR 1118-023,Xiidra |
||
Lifitegrast sodium (SAR-1118) is an LFA-1 antagonist for the therapy of vascular complications of the eye. It inhibits T cell-mediated inflammation by blocking the binding of two cell surface proteins (lymphocyte function-associated antigen 1 and intercel | |||
T77188 | Tifcemalimab | ||
Tifcemalimab (JS004) 是一种人源化抗 BTLA(B 和 T 淋巴细胞衰减因子) 单克隆抗体。Tifcemalimab 通过与 BTLA 结合,阻断 HVEM-BTLA 的相互作用,从而阻断BTLA 介导的抑制信号通路。Tifcemalimab 可用于癌症的研究。 | |||
T76241 |
Trichomide A
|
||
Trichomide A 是一种有效的 SHP2激活剂。Trichomide A 是一种天然的环缩肽。Trichomide A 在 Con A 激活的 T 细胞中对激活的 T 淋巴细胞介导的免疫反应具有免疫抑制活性。Trichomide A 具有研究免疫相关皮肤病的潜力。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7981 |
2-Fluoroadenosine
|
Others | Others |
2-Fluoroadenosine 是淋巴细胞介导的细胞溶解的有效抑制剂。 |